secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-06-08T20:05:07+00:00
Accession:  0001193125-26-261698
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Therapeutics COO Jeremy Chadwick resigns effective June 5, 2026; will advise through Nov 2026
--------------------------------------------------------------------------------

- COO Jeremy Chadwick resigned for personal reasons, not due to any disagreement with company policies.
- Chadwick will remain as an employee advisor until November 2026.
- No replacement COO has been named by the company.
- Chadwick communicated his intention to retire and submitted resignation on June 5, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526261698/0001193125-26-261698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526261698/d13635d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-261698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer